A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease

Kumar, Inder

doi:10.22270/jddt.v11i1.4475

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tmax and half-life increase with multiple dosing. Favipiravir has a short half-life and is rapidly eliminated in the hydroxylated form by renal elimination [22].…”

Section: Pharmacokineticsmentioning

confidence: 99%

A Review on Antiviral Activity of Favipiravir

Palathingal¹,

Archana²,

Kannan³

et al. 2022

JPRI

View full text Add to dashboard Cite

The emerging severe acute respiratory syndrome coronavirus 2 pandemic endangers patients and physicians all over the world. The potency of COVID-19 antiviral drugs is still a matter of debate. The growing understanding of COVID-19 virology and clinical manifestations is resulting in a larger pool of potential pharmacological targets. Favipiravir is included in the treatment regimen of many countries, including some regions of India, that have recently updated their treatment standards and is expected to be an effective treatment for SARS-CoV-2 infection, as it can be used to treat many different types of RNA virus infections such as Ebola, influenza, and the foot-and-mouth disease virus can be treated with this new nucleoside analogue. This review describes the status, mechanisms, pharmacokinetics, and antiviral effect of Favipiravir.

show abstract

“…Tmax and half-life increase with multiple dosing. Favipiravir has a short half-life and is rapidly eliminated in the hydroxylated form by renal elimination [22].…”

Section: Pharmacokineticsmentioning

confidence: 99%

A Review on Antiviral Activity of Favipiravir

Palathingal¹,

Archana²,

Kannan³

et al. 2022

JPRI

View full text Add to dashboard Cite

show abstract

Remdesivir

Bakheit

Darwish

et al. 2023

Profiles of Drug Substances, Excipients and Related Methodology

View full text Add to dashboard Cite

A Critical Assessment of Remdesivir

Chandra,

Choudhary,

Palai

et al. 2024

CDTH

View full text Add to dashboard Cite

The COVID-19 pandemic that originated in Wuhan city, China, has affected every village in India. This has killed millions of people. This disease involves symptomatic and asymptomatic mutations. The purpose of this review was to assess the effectiveness of remdesivir particularly against SAR-CoV-2 (Coronaviridae family). The relevant works have been studied with respect to the drug's chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, clinical data, and side effects. Remdesivir has been used in many cases of coronavirus-infected patients because it has been proven to possess beneficial effects; however, significant adverse effects have also been reported. Remdesivir has been reported to help in lowering the disease's high fatality rate. However, the WHO has warned against using the medicine because there is no clinical data to support its therapeutic efficacy.

show abstract

A review on pharmacokinetics, pharmacodynamics and clinical aspects of remdesivir and favipiravir for the treatment of coronavirus disease

Cited by 3 publications

References 36 publications

A Review on Antiviral Activity of Favipiravir

A Review on Antiviral Activity of Favipiravir

Remdesivir

A Critical Assessment of Remdesivir

Contact Info

Product

Resources

About